| abstract |
The present invention relates to a compound represented by the formula (I) or a salt thereof [wherein R 2 is H, C 1-3 alkyl, n-butyl, C 1-2 fluoroalkyl, cyclopropyl, cyclobutyl, (cyclo Propyl) methyl-, —CN or —CH 2 OH; R 3 is, inter alia, an optionally substituted C 4-7 cycloalkyl or an optionally substituted heterocyclic group (aa ), (Bb) or (cc); R a is H, methyl or ethyl; R b is H or methyl; R 4 is H, methyl, ethyl, n-propyl, —C (O) -Me or —C (O) —C 1 fluoroalkyl; and R 5 is —C (O) — (CH 2 ) n—Ar, —C (O) —Het, —C ( O) -C 1-6 alkyl, -C (O) -C 1 fluoroalkyl, -C (O)-(CH 2 ) 2 -C (O) -NR 15b NR 15b , -C (O) -CH 2 -C (O) -NR 15b NR 15b , -C (O) -NR 15b- (CH 2 ) m 1 -Ar, -C (O) -NR 15b -Het, -C (O) -NR 15b -C 1-6 alkyl, -C (O) -NR 5a R 5b , -S (O) 2- (CH 2 ) m 2 -Ar, -S (O) 2 -Het, -S (O) 2- C 1-6 alkyl or —CH 2 —Ar; or R 4 and R 5 together represent — (CH 2 ) p 1 —, — (CH 2 ) 2 —X 5 — (CH 2 ) 2- , -C (O)-(CH 2 ) p 2- , -C (O) -N (R 15 )-(CH 2 ) p 3- ; or NR 4 R 5 is a partial formula ( y), (y1), (y2) or (y3)]. The present invention further relates to the use of the compounds as inhibitors of type IV phosphodiesterase (PDE4) and / or inflammatory and / or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, Also provided is the use of said compounds for treating and / or preventing rheumatoid arthritis, allergic rhinitis, psoriasis or atopic dermatitis). |